Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START Trial in metastatic kidney cancer
NCT01217931Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2011
- Primary completion
- Jan 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of everolimus, bevacizumab and pazopanib in renal cell carcinoma (RCC) (6 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Time to Overall Treatment Failure at 4 weeks. Started Jan 2011; status: active, not recruiting.
02
Drugs
everolimusbevacizumabpazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01217931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01217931.